- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 213/73 - Unsubstituted amino or imino radicals
Patent holdings for IPC class C07D 213/73
Total number of patents in this class: 560
10-year publication summary
|
41
|
34
|
45
|
48
|
52
|
36
|
40
|
35
|
38
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Vertex Pharmaceuticals Incorporated | 1570 |
15 |
| Bristol-myers Squibb Company | 4886 |
14 |
| Qingdao Kingagroot Chemical Compound Co., Ltd. | 144 |
11 |
| Novartis AG | 11297 |
10 |
| Centre National de La Recherche Scientifique | 10052 |
9 |
| Northwestern University | 3271 |
9 |
| Board of Regents, The University of Texas System | 5604 |
8 |
| Merck Patent GmbH | 5849 |
7 |
| Bayer Pharma AG | 1085 |
7 |
| E. I. du Pont de Nemours and Company | 4253 |
6 |
| Abbvie Inc. | 1781 |
6 |
| Celgene Quanticel Research, Inc. | 167 |
6 |
| Oryzon Genomics S.A. | 105 |
6 |
| Vivace Therapeutics, Inc. | 27 |
6 |
| Merck Sharp & Dohme LLC | 3742 |
6 |
| F. Hoffmann-La Roche AG | 7942 |
5 |
| BASF SE | 20367 |
5 |
| Bayer AG | 3202 |
5 |
| Bayer Cropscience AG | 2143 |
5 |
| Amgen Inc. | 3894 |
5 |
| Other owners | 409 |